EA201600291A2 - WATER COMPOSITION FOR INSTALLATIONS IN URINARY BUBBLE - Google Patents

WATER COMPOSITION FOR INSTALLATIONS IN URINARY BUBBLE

Info

Publication number
EA201600291A2
EA201600291A2 EA201600291A EA201600291A EA201600291A2 EA 201600291 A2 EA201600291 A2 EA 201600291A2 EA 201600291 A EA201600291 A EA 201600291A EA 201600291 A EA201600291 A EA 201600291A EA 201600291 A2 EA201600291 A2 EA 201600291A2
Authority
EA
Eurasian Patent Office
Prior art keywords
sorbitol
mannitol
cystitis
inclusion
hyaluronic acid
Prior art date
Application number
EA201600291A
Other languages
Russian (ru)
Other versions
EA201600291A3 (en
Inventor
Ирина Николаевна Прадхан
Александр Николаевич Воробьев
Original Assignee
Общество с ограниченной ответственностью "ФармСинергия"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью "ФармСинергия" filed Critical Общество с ограниченной ответственностью "ФармСинергия"
Publication of EA201600291A2 publication Critical patent/EA201600291A2/en
Publication of EA201600291A3 publication Critical patent/EA201600291A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к медицине и химико-фармацевтической промышленности и представляет собой раствор для временной защиты слизистой оболочки мочевого пузыря при различного рода манипуляциях: при уретро-цистоскопии, лучевой терапии, при лечении циститов различной этиологии, вызывающих раздражение стенки мочевого пузыря (хроническом цистите, лучевом цистите, интерстициальном цистите) и т.д. Техническим результатом предлагаемого изобретения является создание новой водной композиции, которая обладает повышенным защитным эффектом в отношении клеток уротелия после окислительного стресса за счет включения в композицию маннита или сорбита; повышенным антимикробным действием и защитой уротелия за счет включения цинка хлорида; контролируемой вязкостью за счет включения маннита или сорбита и цинка хлорида. Указанный технический результат достигается при использовании водной композиции для инстилляции в мочевой пузырь на основе гиалуроновой кислоты и хондроитина сульфата, которая отличается тем, что дополнительно содержит маннит или сорбит в соотношении к сумме гиалуроновой кислоты и хондроитина сульфата, равном 0,014-4,2 при следующем содержании компонентов в водном растворе, мас.%: гиалуроновая кислота - 0,05-1,6, хондроитин сульфата - 0,07-2,0, маннит или сорбит - 0,05-0,5, вода - остальное до 100. Кроме того, водная композиция дополнительно содержит хлорид цинка, взятый в количестве 0,7-1,9 мас.%.The invention relates to medicine and pharmaceutical industry and is a solution for the temporary protection of the mucous membrane of the bladder with various manipulations: with urethro-cystoscopy, radiation therapy, in the treatment of cystitis of various etiologies that cause irritation of the bladder wall (chronic cystitis, radiation cystitis interstitial cystitis, etc. The technical result of the invention is the creation of a new water composition, which has an increased protective effect against urothelium cells after oxidative stress due to the inclusion of mannitol or sorbitol in the composition; increased antimicrobial action and protection of urothelia due to the inclusion of zinc chloride; controlled viscosity due to the inclusion of mannitol or sorbitol and zinc chloride. This technical result is achieved when using an aqueous composition for instillation into the bladder based on hyaluronic acid and chondroitin sulfate, which is characterized in that it additionally contains mannitol or sorbitol in relation to the sum of hyaluronic acid and chondroitin sulfate, equal to 0.014–4.2 with the following content components in aqueous solution, wt.%: hyaluronic acid - 0.05-1.6, chondroitin sulfate - 0.07-2.0, mannitol or sorbitol - 0.05-0.5, water - the rest is up to 100. Except Moreover, the aqueous composition additionally contains chlori d zinc, taken in the amount of 0.7-1.9 wt.%.

EA201600291A 2015-03-24 2016-04-27 WATER COMPOSITION FOR INSTALLATIONS IN URINARY BUBBLE EA201600291A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2015110118/15A RU2586285C1 (en) 2015-03-24 2015-03-24 Aqueous composition for instillation in bladder

Publications (2)

Publication Number Publication Date
EA201600291A2 true EA201600291A2 (en) 2016-09-30
EA201600291A3 EA201600291A3 (en) 2016-11-30

Family

ID=56115349

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201600291A EA201600291A3 (en) 2015-03-24 2016-04-27 WATER COMPOSITION FOR INSTALLATIONS IN URINARY BUBBLE

Country Status (2)

Country Link
EA (1) EA201600291A3 (en)
RU (1) RU2586285C1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2677195C1 (en) * 2017-12-28 2019-01-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" Method of treatment of urolithiasis in carnivores
RU2751649C1 (en) * 2020-08-24 2021-07-15 Наталья Геннадиевна Галкина Method for treatment and prevention of cystitis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2554489A1 (en) * 2004-01-28 2005-08-11 The Regents Of The University Of California Novel interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis

Also Published As

Publication number Publication date
RU2586285C1 (en) 2016-06-10
EA201600291A3 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
DOP2022000038A (en) ENHANCED LIPID NANOPARTICLES FOR NUCLEIC ACID DELIVERY
EA201691147A1 (en) ION WATER COMPOSITIONS
BR112015026297A2 (en) combination therapy consisting of a tor kinase inhibitor and a substituted 5-quinazolinone compound for cancer treatment
EA201591743A1 (en) STIMULATORS sGC
BR112015025784A2 (en) method for reducing gram positive bacteria in human skin, liquid cleansing formulation and method for cleaning human skin
MY182507A (en) Aqueous ophthalmic solution
AR099707A1 (en) COMPOSITIONS AND METHODS TO TREAT RENAL DISORDERS
BR112017013674A2 (en) methods and compositions for treating brain diseases.
BR112016029012A2 (en) method of treating non-small cell lung cancer and / or small cell lung cancer using thienotriazolodiazepine compounds
CL2016001272A1 (en) Water mold control method in water dedicated to aquaculture.
EA201600291A2 (en) WATER COMPOSITION FOR INSTALLATIONS IN URINARY BUBBLE
BR112017000481A2 (en) treatment method and circulating water treatment system circulating through wet type booth
PH12015501739B1 (en) Topical antifungal composition for treating onychomycosis
SA521420975B1 (en) Nanostructured Formulations for The Delivery of Silibinin and Other Active Ingredients for Treating Ocular Diseases
BR112013033060A2 (en) ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol
AR097069A1 (en) TREATMENT FLUIDS CONTAINING A PERFLUORATED CHELATING AGENT AND METHODS FOR USE
BR112017011912A2 (en) hair deformation treatment agent
BR112017014016A2 (en) intraocular pressure reduction method; and, pharmaceutical composition.
BR112015022134A2 (en) compound, pharmaceutical composition, patch, stick, spray dispenser, tube or pen, and method of treating an infection
EA201691528A1 (en) WATER COMPOSITION CONTAINING OLIGODYNAMIC METAL
EA201891008A3 (en) TREATMENT OF SYMPTOMS ASSOCIATED WITH ANDROGEN-DEPRIVATION THERAPY
BR112015000186A2 (en) use of zinc coceth sulfate as antibacterial agent against propionibacterium acnes
WO2012016228A3 (en) Compositions and methods for mitigating adverse effects of exposure to chlorinating and/or brominating agents
AR103636A1 (en) METHODS OF TREATMENT OF POSTERPEPTIC NEURALGY WITH A TOPICAL FORMULATION OF AN ESPIRO-OXINDOL COMPOUND
AR095020A1 (en) CONDOM